Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Interleukin 5 receptor beta chain (IL-5Rβ), also known as CD131 or the common beta chain (βc), is a shared subunit of the IL-3, IL-5, and GM-CSF receptors. It does not bind IL-5 directly, but forms a high-affinity receptor complex with the IL-5 specific alpha chain (IL-5Rα) upon ligand binding. The beta chain is crucial for signal transduction, activating JAK kinases and downstream signaling pathways involved in eosinophil proliferation and differentiation. As a therapeutic target, blocking IL-5 signaling through the beta chain is of interest for treating eosinophil-driven diseases like asthma and allergic inflammation. Because it is shared among multiple cytokine receptors (IL‑3R & GM-CSFR), it plays broader roles in hematopoiesis regulation.
Blocking IL-5 binding or receptor complex formation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 5 Receptor Beta Chain (βc).